October 22, 2025
Authored and Edited by Luke H. MacDonald, Ph.D.; Sonja W. Sahlsten
In Magēmā Technology LLC v. Phillips 66, No. 2024-1342 (Fed. Cir. Sept. 8, 2025) the Federal Circuit reversed denial of a motion for a new trial after the defendant argued it needed testing data to prove infringement when it had previously represented that testing data would be too dangerous to obtain.
Magēmā alleged Phillips’ refineries infringed a patent relating to desulfurizing heavy marine fuel oil (HMFO) to comply with international sulfur content standards. Right before jury selection, Phillips introduced a new noninfringement theory by arguing Magēmā could not prove infringement without actual product testing data. Magēmā timely objected, contending Phillips had prevented Magēmā from accessing testing data because, during discovery, Phillips argued it would be too dangerous to obtain. The judge overruled the objection, Phillips presented its theory, and the jury found for Phillips.
The court subsequently denied Magēmā’s motion for a new trial, finding Phillips’ new theory improper and prejudicial, but harmless.
The Federal Circuit reversed and remanded for a new trial, holding the new theory not harmless. Because the jury’s verdict did not specify its reasoning, the Court could not be reasonably certain it was untainted by Phillips’ improper and untimely theory. The Court instructed that Phillips may not argue on remand that it needs testing data for infringement.
The Court also affirmed the district court’s construction of “HMFO,” holding the specification “clearly and expressly” defines it, and rejected Phillips’ alternative grounds for affirmance of the verdict.
Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.